Evidence mapPaperPMID 37620972Full record

ArticleJournal of orthopaedic surgery and research2023

PPARγ activation suppresses chondrocyte ferroptosis through mitophagy in osteoarthritis.

Xiang Xue, Tianming Dai, Junyan Chen, Yangyang Xu, Zhenyu Yang, Jian Huang, Wuyan Xu, Siming Li, Qingqi Meng

Open access · goldAbstract read
In one paragraph

Article in Journal of orthopaedic surgery and research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. PLA2G2F suppresses ferroptosis through phospholipid remodeling.Nature structural & molecular biology · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. RETRACTED: PTEN Deficiency Induced by Extracellular Vesicle miRNAs fromInternational journal of molecular sciences · 2024
    Article
  16. Ferroptosis in Arthritis: Driver of the Disease or Therapeutic Option?International journal of molecular sciences · 2024
    Review
  17. Review
  18. PDK4 inhibits osteoarthritis progression by activating the PPAR pathway.Journal of orthopaedic surgery and research · 2024
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Xiang Xue *Department of Orthopedics, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, China.
Tianming Dai *Guangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, China.
Junyan ChenGuizhou Medical University, Guiyang, China.
Yangyang XuGuizhou Medical University, Guiyang, China.
Zhenyu YangDepartment of Orthopedics, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, China.
Jian HuangDepartment of Traumatic Orthopedics, The Central Hospital of Xiaogan, Xiaogan, China.
Wuyan XuDepartment of Orthopedics, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, China.
Siming LiGuangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, China. drsmli@163.com.
Qingqi MengGuangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, China. mengqingqi@jnu.edu.cn.
Jinan University · CNGuiyang Medical University · CNThe Central Hospital of Xiao gan · CN

Funding

Guangdong Provincial Natural Science Foundation 2019A1515011085Science and Technology Program of Guangzhou 202102080344
6 · The paper itself

Abstract

backgroundOsteoarthritis (OA) is a prevalent disease plaguing the elderly. Recently, chondrocyte ferroptosis has been demonstrated to promote the progression of OA. Peroxisome proliferator-activated receptor-γ (PPARγ) is an important factor in maintaining cartilage health. However, the relationship between PPARγ and chondrocyte ferroptosis in OA and its mechanism is completely unclear.

methodsWe established a surgically induced knee OA rat model to investigate PPARγ and chondrocyte ferroptosis in OA. Rat knee specimens were collected for Safranin O/Fast Green staining and immunohistochemical staining after administered orally placebo or pioglitazone (PPARγ agonist) for 4 weeks. We used RSL3 to establish a chondrocyte ferroptosis model cultured in vitro to study the role of PPARγ activation toward ferroptosis, mitochondrial function, and PTEN-induced putative kinase 1 (Pink1)/Parkin-dependent mitophagy. GW9662 (PPARγ antagonist), Mdivi-1 (mitophagy inhibitor), and chloroquine (mitophagy inhibitor) were employed to investigate the mechanism of PPARγ-Pink1/Parkin-dependent mitophagy in the inhibition of ferroptosis.

resultsWe found that PPARγ activation by pioglitazone attenuated not only OA but also inhibited the expression of the ferroptosis marker acyl-CoA synthetase long-chain family member 4 (ACSL4) at the same time in rats. Furthermore, in vivo and in vitro data indicated that PPARγ activation restored Pink1/Parkin-dependent mitophagy, improved mitochondrial function, inhibited chondrocyte ferroptosis, and delayed the progression of OA.

conclusionsThe present study demonstrated that PPARγ activation attenuates OA by inhibiting chondrocyte ferroptosis, and this chondroprotective effect was achieved by promoting the Pink1/Parkin-dependent mitophagy pathway.

Indexed as

FerroptosisMitophagyOsteoarthritis, KneePPAR gammaAnimalsChondrocytesPioglitazoneProtein KinasesQuinazolinonesRats3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinonePioglitazonePPAR gammaProtein KinasesQuinazolinonesChondrocyteFerroptosisMitophagyOsteoarthritisPink1PPARγ

Identifiers

PMID37620972
PMCPMC10463860
OpenAlexW4386135075

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.